AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2690-1919/247
1 Endocrinology Division, Olive View-UCLA Medical Center, David Geffen School of Medicine, CA, USA.
2 Department of Medicine, Olive View-UCLA Medical Center, David Geffen School of Medicine, CA, USA.
*Corresponding Author: NASSER Mikhail, Endocrinology Division, Olive View-UCLA Medical Center, David Geffen School of Medicine, CA, USA.
Citation: : NASSER Mikhail and Soma Wali. (2022). Graves’ disease Induced by Sars-Cov-2 Vaccination. J Clinical Research and Reports, 11(2); DOI:10.31579/2690-1919/247
Copyright: © 2022, NASSER Mikhail. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 01 April 2022 | Accepted: 20 April 2022 | Published: 30 April 2022
Keywords: COVID-19; vaccine; Graves’ disease; hyperthyroidism; mechanisms; thyrotropin-receptor antibodies; ASIA; TPO
Background: Several cases of Graves’ disease were recently reported in individuals vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Objective: To determine characteristics and patterns of Graves’ disease occurring following SARS-CoBV-2 vaccination.
Methods: PubMed search up to March 31st, 2022. Search terms are Graves’ disease, SARS-Cov-2, vaccine, COVID-19. Case reports, case series, review articles and pertinent in vitro studies are reviewed.
Results: Review of literature revealed 28 cases (19 women) of new onset and 5 cases (4 women) of relapses of Graves’ disease after receiving different types of vaccines against coronavirus disease 2019 (COVID-19). Onset of hyperthyroid symptoms started 2-60 days after vaccination and occurred more frequently after the first vaccine dose (n=13) than after the second dose (n=5). In 70% of cases (23 of 33), the implicated agent was the m-RNA based vaccine of Pfizer-BioNtech. Severity of Graves’ disease symptoms was generally moderate and controlled by anti-thyroid medications (mainly methimazole) and beta-adrenergic blockers. The course of Graves’ disease is unclear as patients are still receiving therapy. No specific risk factors could be defined that may increase predisposition to the COVID-19 vaccine-induced Graves’ disease. Mechanisms of development of Graves’ disease after COVID-19 vaccination are unclear but may be related to the phenomena of molecular mimicry or autoimmune/inflammatory syndrome by adjuvants (ASIA).
Conclusions: The timing of onset of symptoms of Graves’ disease in relation to the administration of COVID-19 vaccine strongly suggests a causal relationship. Physicians should be aware of the occurrence of this uncommon adverse effect.
Graves’ disease, the most common cause of hyperthyroidism, is an autoimmune disease due to activating autoantibodies directed against the thyrotropin receptors [1]. After the widespread use of SARS-CoV-2 vaccination, several cases of new-onset or recurrent Graves’ disease were reported throughout the world. The main purpose of this article is to analyze characteristics of these cases. Confirmation of diagnosis of Graves’ disease was demonstrated by documentation of hyperthyroid symptoms and signs, elevation of circulating thyroid hormones and high titers of thyrotropin-receptor antibodies. The latter have 99% sensitivity and specificity for Graves’ disease [1].
Characteristics of COVID-19 induced Graves’ disease
28 cases of newly diagnosed [2-16] and 5 cases [3,9,17] of relapsed Graves’ disease were reported after receiving COVID-19 vaccination (tables 1 and 2). 23 of the 33 patients were women reflecting the usual female predominance of Graves’ disease. Age range was 28-71 years. 5 patients had history of other thyroid diseases: 2 patients had Hashimoto’s (autoimmune) thyroiditis, 2 had nodular goiter, and 1 patient had “hypothyroidism”. Family history of autoimmune thyroid disease or autoimmune diseases in general was recorded in 4 patients. However, family history was not documented in approximately half of patients. The onset of hyperthyroid symptoms occurred 2-60 days after vaccination. In recurrent cases, relapse was diagnosed 2 months to 30 years (median 8 years) after the first episode of Graves’ disease (table 2). In 13 patients, hyperthyroidism started after the first vaccine dose, in 5 patients after the second dose, and was not specified in the remaining patients. No clear characteristics or precipitating factors that might predispose patients to develop Graves’ disease could be identified. The most common implicated vaccine was the Pfizer-BioNTech vaccine (m-RNA based) reported in 23 of the 33 (70%) patients, followed by Oxford-AstraZeneca (recombinant adenovirus vector-based) in 6 patients, and Moderna (mRNA-based) in 3 patients [18-20]. Overall, the severity of hyperthyroidism was moderate and easily controlled by anti-thyroid medications (mainly methimazole) and beta-adrenergic blockers. However, one 38-year-old woman reported by Weintraub et al [10] presented with thyrotoxic crisis (thyroid storm). No deaths were reported. With respect to the disease outcome, as of the date of writing, all patients are currently under treatment which usually takes 12-18 months [1]. The close timing relationship between vaccine administration and development of Graves’ disease provides the strongest evidence that SARS-CoV-2 vaccination may be causally related to Graves’ disease. In addition, 3 of the 5 relapsed cases occurred 8-30 years after the initial episode of Graves’ disease [3,9,17]. It is very uncommon for relapses of Graves’ disease to take place after such long duration [21]. Hence, it is unlikely that relapsed cases are simply a coincidence.
Reference/country | Age/gender | Type of vaccine (written as in original article) | Timing of onset of hyperthyroid symptoms | Comment |
1.Vera-Lastra et al (Mexico) [2] | 40/F | Pfizer-BioNTech | 2 days after first dose | Had COVID-19, 8 months before vaccination |
2.Vera-Lastra et al [2] | 28/F | Pfizer-BioNTech | 3 days after first dose |
|
3.Zettinig & Krebs (Austria) [3] | 46/M | Pfizer-BioNTech (Tozinameran) | 15 days after first dose |
|
3.diFilippo et al (Italy) [4] | 32/M | Oxford-AstraZeneca (Vaxzevria) | 10 days after second dose | Ex-smoker* |
5.diFilippo et al [4] | 35/M | Oxford-AstraZeneca (Vaxzevria) | 5 days after the first dose | Ex-smoker* |
6.Lui et al (China) [5] | 40/F | BNT162b2 mRNA Pfizer BioNtech | 5 weeks after second dose | 8-year history of hypothyroidism |
7.Sriphapradang and Shantavasinkul (Thailand) [6] | 70 y/M | ChAdOx1 nCoV-19 | 2 days after second dose |
|
8.Peris et al (Spain) [7] | 71/F | Pfizer | 60 days |
|
9.Peris et al [7] | 42/F | Pfizer | 10-14 days |
|
10.Peris et al [7] | 54/F | Moderna | 10-14 days |
|
11.Peris et al [7] | 46 y/F | Pfizer | 50 days |
|
12.Shih et al (Taiwan) [8] | 39/F | Moderna (Spikevax) | 2 weeks | History of euthyroid autoimmune thyroid disease |
13.Shih et al [8] | 59 y/F | Vaxzevria (AstraZeneca) | 2 weeks | Sister has hyperthyroidism |
14.Shih et al [8] | 44/F | Vaxzevria (AstraZeneca) | 4 days |
|
15.Bostan et al (Turkey) [9] | 54/F | Pfizer BioNtech | 1 week after first dose (received 2 doses 1 month apart) | 2-year history of Hashimoto’s thyroiditis |
16.Bostan et al [9] | 51/F | Pfizer BioNtech | 4 days after the second dose | Rapidly progressive ophthalmopathy |
17.Bostan et al [9] | 47/F | Pfizer BioNtech | 5 days after first dose | Hyperthyroid symptoms did not worsen after second dose |
18.Bostan et al [9] | 46/M | Pfizer BioNtech | 3 weeks after second dose |
|
19.Weintraub et al (USA) [10] | 38/F | Pfizer BioNtech | 5 days after first dose. She decided to postpone second dose. | Presented with thyroid storm. Had enlarged thyroid gland shown 1 year earlier by computed tomography |
20.Weintraub et al [10] | 63/F | Moderna | 1 week after first dose. Received 2 doses | Has sister and aunt with lupus |
21.Weintraub et al [10] | 30/M | Pfizer BioNtech | 4 weeks after first dose | Mother has Grave’ s disease |
22.Goblirsch et al (USA) [11] | 71/F | Pfizer BioNtech | 14 days after second dose | Patient had multinodular goiter |
23.Hamouche et al (USA) [12] | 32/M | Pfizer BioNtech | 22 days after first dose | Patient was diagnosed with COVID-19 10 days after vaccination |
24.Patrizio et al (Italy) [13] | 52 /M | Pfizer BioNtech | 4 weeks after second dose | Patient has vitiligo and develops type 1 diabetes at the same time of Grave’s disease |
25.Pujol et al (Spain) [14] | 38/F | Pfizer BioNtech | 12 days after first dose |
|
26.Raven et al (Australia) [15] | 35/F | Adenovirus-vectored (AZD1222) | 5 days after vaccine | Both grandmothers have history of thyroid disease |
27. Oğuz et al (Turkey) [16] | 40/F | CoronaVac 2 doses followed by BNT162b2 (Pfizer) | 2 days after BNT162b2 (Pfizer) |
|
28. Oğuz et al [16] | 29/M | CoronaVac 2 doses followed by BNT162b2 (Pfizer) | 9 days after BNT162b2 (Pfizer) | History of nodular goiter and ankolysing spondylitis |
*Smoking is one risk factor for Graves’ disease [1].
Table 1: Cases of new onset Grave’s disease after COVID-19 vaccination
Reference/Country | Age/gender | Time since remission of Graves | Type of vaccine | Timing of onset of hyperthyroid symptoms | Comment |
1.Zettinig & Krebs (Austria) [3] | 71/F | Since 2004 (17 years) | Pfizer BioNtech (Tozinameran) | 34 days after second dose |
|
2.Pierman et al (Belgium) [17] | 34/F | Since 2014 (8 years) | Pfizer BioNtech | 10 days after first dose | Symptoms worsened after receiving second vaccine dose 34 days after first dose |
3.Bostan et al (Turkey) [9] | 44/F | 30 years | Inactivated vaccine (CoronaVac) | 1 week after first dose |
|
4.Bostan et al [9] | 49/M | 1 year | Pfizer BioNtech | 1 month after second dose |
|
5.Bostan et al [9] | 31/F | 2 months | Pfizer BioNtech | 3 weeks after first dose |
|
Table 2. Cases of relapses of Grave’s disease after COVID-19 vaccination
Mechanisms of COVID-19 vaccine induced Graves’ disease
The mechanisms underlying vaccine-induced Graves’ disease are not fully understood. In this regard, there are 2 main theories: the molecular mimicry or cross-reactivity theory and the autoimmune/Inflammatory syndrome induced by adjuvants (ASIA).
1. Molecular mimicry theory
Molecular mimicry refers to a close similarity between certain pathogenic elements contained in the vaccine and specific human proteins [22]. It follows that cross-reactivity may occur when amino acid homology exists between the pathogen and a given self-tissue protein. Thus, antibodies developed against the spike protein of SARS-CoV-2 following COVID-19 vaccination might cross react with human thyroid tissues to trigger an autoimmune disorder such as Graves’ disease in susceptible individuals. In fact, Vojdani et al [23] have shown that anti-spike antibodies of SARS-CoV-2 react in vitro with human thyroid peroxidase (TPO). Furthermore, they found that SARS-CoV-2 protein shared a 50-70% of peptide sequences with TPO [23]. Unfortunately, Vojdani et al [23] did not evaluate cross-reactivity between the anti-SARS-CoV-2 spike protein and thyrotropin receptors which are more relevant to Graves’ disease compared with TPO [1].
2. The ASIA theory
The ASIA theory entails development of an autoimmune disease due to the use of adjuvants in the vaccine. Adjuvants are immunological molecules that potentiate antigen specific immune response. These molecules are frequently employed in vaccination production to increase immunogenicity repose of a vaccine. This results in a reduced frequency and amount of vaccination required to achieve adequate immunity [24]. However, in predisposed subjects, adjuvants may trigger autoimmune diseases [25].
This review raises 3 important practical questions. First, is there any risk for patients with actual Graves’ disease if they receive COVID-19 vaccine? Unfortunately, very limited data exist with respect to the effects of COVID-19 vaccine on patients who already have Graves’ disease. In a report from Thailand, Sriphapradang [26] described a 30-year-old woman with Graves’ disease whose hyperthyroid symptoms worsened 4 days after receiving a booster dose of the Oxford-AstraZeca (Vaxzevria) vaccine [19]. Meanwhile, in our busy thyroid disease clinics, we did not observe any evidence of exacerbation of Graves’ disease following COVID-19 vaccination. Nevertheless, Graves’ patients should be counselled about possible worsening of hyperthyroid symptoms after vaccination. Second, should patients with past-history of Graves’ disease receive COVID-19 vaccine? As shown in table 2, 5 cases had relapses of Graves’ disease after receiving COVID-19 vaccine. Therefore, patients should be counselled about possible relapse after vaccination. Finally, should patients with COVID-19 vaccine induced Graves’ disease receive a booster vaccine dose? In this respect, 2 such cases were reported by Bostan et al [9] (table 1) and Pierman et al [17] (table 2). The first patient was a 47-year-old woman who was diagnosed with Graves’ disease after onset of hyperthyroidism 5 days after the first dose of Pfizer-BioNtech vaccine. No worsening of symptoms occurred after she received the second dose of the same vaccine (exact timing not reported) [9]. Conversely, the second patient who was 34-year-old woman had aggravation of hyperthyroid symptoms shortly after receiving the booster Pfizer-BioNtech vaccine [17]. Given the devastating consequences of COVID-19 infection, it may be still reasonable to give a booster vaccine dose. Yet, we suggest monitoring thyroid function very closely for approximately 2 months after receiving the booster vaccine dose for optimum control of hyperthyroid symptoms. Clearly, more data are needed to determine the ideal approach for the above 3 situations.
28 cases of new-onset and 5 cases of relapsed Graves’ disease were reported 2-60 days following the administration of different types of SAR-CoV-2 vaccines. This number of cases is most likely underreported, but the true incidence may be still considered rare given the millions of people who received the vaccine worldwide. Most cases were related to the Pfizer-BioNtech vaccine. It is unclear whether this observation is real or a result of reporting bias. Physicians should be aware of the possible occurrence of new-onset or relapsed Graves’ disease following the administration of COVID-19 vaccines. Thus, if patients complain of hyperthyroid symptoms, laboratory investigations should be performed to clarify the etiology. Interestingly, in the latest prescribing information of the 2 mRNA COVID-19 vaccines produced by Pfizer-BioNtech and Moderna, there was no mention of Graves’ disease among the rare adverse effects of the vaccines occurring during clinical trials or in the post-marketing period [18, 20]. All cases of COVID-19 vaccine induced Graves’ disease should be reported to the Federal Drug Administration (FDA) and the vaccine manufacturer to clarify the exact link between COVID-19 vaccines and Graves’ disease.
The authors do not conflict of interest to declare.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
